

PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sul	bstitute for form 1449/PTO)		Complete if Known		
				Application Number	10/595,934-Conf. #9188	
11	NFORMATIO	N DI	SCLOSURE	Filing Date	May 19, 2006	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Mladen Mercep	
				Art Unit	N/A	
ł	(Use as many s	he ets as	necess ary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	03818/0204417-US0	

U.S. PATENT DOCUMENTS							
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where		
Initials*	No.1	Number-Kind Code ² (if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear		
	AA*	US-6,511,976	01-28-2003	Andres-Gil et al.			
	AB* US-4,145,434 03-20-1979 V		VAN DER Burg et al.				
	AC*	US-3,711,489	01-16-1973	Lombardino			
	AD*	US-4,198,421	04-15-1980	Cherkofsky et al.			

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
ı	ВА	WO-99/19317 ,	04-22-1999	Janssen Pharmaceutica N.V.		一
	ВВ	WO-97/38991	10-23-1997	Janssen Pharmaceutica N.V.		
	ВС	WO-96/14320	05-17-1996	Janssen Pharmaceutica N.V.		
	BD	WO-96/14321	05-17-1996	Janssen Pharmaceutica N.V.		П
	BE	CA-967,573	05-13-1975	Pfizer Inc.		П
	BF	FR-2,504,140 ·	10-22-1982	Centre Nat Rech Scient		
	BG	EP-0063525	10-27-1982	Centre National de la Recherche Scientifique		
	вн	WO-03/099822	12-04-2003	Pliva D D et al.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Therefore that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. It is indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	CA .	Gansser C. et al., " Determination of the radioprotective activity of certain analogs of imipramine" Ann. Pharmaceutiques Francaises. 1983, vol 41: pages 465-471	
	CB .	Olivera R. et al., "Dibenzoxepino [4,5-d]pyrazoles: a facile approach via the Ullmann-ether reaction"Tetrahedron Letters, 2000, vol. 41: 4353-4356, 4357-4360	
	cc .	Kawashima K., et al, "Synthesis of Dibenzo [b,f] azepine Derivatives. III. Introduction of a Cyclopropane Ring by Therman Decomposition of a Pyrazoline" Takeda Kenkyusho Ho, 1978, vol. 37: pages 6-11.	
	CD .	Fichou D. et al., "Regioselectivite De La Cycloaddition Dipolaire1,3" Tetrahedron, 1984, vol. 40:, No. 24, pp. 5121-5133	
	CE .	Saucier, C. et al. "Identification of an Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Involves Decereases in Receptor RNA and Number" Journal of Neurochemistry, 1997, vol 68; No. 1, pages 1998 - 2011	
	CF ,	Wolf., W.A. et al. "The Serotonin 5-HT 2C Receptor Is a Prominent Serotonin Receptor in Basal Ganglia: Evidence from Functional Studies on Serotonin-Mediated Phosphoinositide Hydrolysis" Journal of Neurochemistry, 1997, vol. 69: pgs. 1449	

Examiner	/Amy Lewis/	Date	11/08/2000
Signature	· · · · · · · · · · · · · · · · · · ·	Considered	11/00/2009

PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	bstitute for form 1449/PTO			Complete if Known		
				Application Number	10/595,934-Conf. #9188	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	May 19, 2006	
S	TATEMENT E	3Y /	APPLICANT	First Named Inventor	Mladen Mercep	
				Art Unit	N/A	
	(Use as many she	ets as	necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	03818/0204417-US0	

	CG 	Thomson W. et al. "Juvenile Idiopathic Arthritis Genetics - What's new? What's next? Arthritis Research, 2002, vol 4 and 5: pgs 302-306
	CH	Millan, M.J. et al, "S18126 ({2-4-2,3-dihydrobenzo[1,4] dioxin-6-yl)piperazin-1-ylmethyl}), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In vitro and In Vitro and In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride, 1998, Journal of Pharmacology and Experimental Thereapeutics, vol 287: No. 1 pages 167-186.
(CI	T.F. Meert, et al. " Psychopharmacology of Ritanserin: Comparison with Chlordiazepoxide", Drug Development Research, 1989, vol. 18, pgs.119-144
(C1	F.Bymaster, et al , " New Approaches to developing antidepressants by enhancing monoaminergic neurotransmission" Expert Opinion Investig. Drugs 2003, 12, 531-543
	CK	U. Spampinato, et al. " Role of Striatal Serotonin 2A and Serotinin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum" J. Neurochemistry 2000, vol. 74, pgs. 693-701
	CL	F.P. Monnet, et al . "N-Methyl-D-aspartate-induced neuronal activiation is selectively modulated by σ receptors", European Journal of Pharmacology, 1990, vol. 179, pgs. 441-445.
	CM :	Claghorn, J. et al, "Recent developments in antidepressant agents" Progress in Drug Research Clinic Inc. 1996 , vol.46, pgs.243-262;
	CN .	Sperling, W. et al " New Tetracyclic Antidepressants" Drugs <i>Today</i> , 1997 , vol. 33, No. 2, pgs. 95-102.
	co	J. Ignacio Andres et al. " R107500.A new 5-HT 2A/2C Antagonist with Potential Anxiolytic Profile" Drugs Fut. 2002, vol. 27, Suppl. A: C41
	CP .	Jose M. Cid, et al., " Synthesis of 2-aminomethyl-3, 3a, 8, 12, "Drugs Fut. 2002 , vol 27, Suppl. A: P182
	cq,	Niemegeers, CJ.E., et al, "Interaction of Drugs with Apomorphine, Tryptamine and Norepinephrine. A New 'in vivo" Approach: the ATN-Test in Rats", Arch. Int. Pharmacodyn. Vol. 227, pages 238-253 (1977).
	CR ,	Berge S. M. et al. "Pharmaceutical Salts," Journal of Pharmaceutical Sciences., 1977; Vol. 66: pages 1-20
	cs ,	Bonhaus D.W., et al, "The pharmacology and distribution of human 5-hydroxytryptamine2B (5HT2B) receptor gene products: comparison with 5-HT2A and 5HT2C receptors" British Journal of Pharmacology, (1995), Vol, 115: pages 622-628
	CT ,	Porsolt R.D. et al. " Behavioural Despair in Mice: A Primary Screening Test for Antipressants" Arch. Int. Pharmacodyn. Vol. 229, pages 327-336 (1977)
(CU .	PCT International Search Report for International Application No. PCT/HR2004/000053, Dated April 18, 2005.
/	CV	Olivera, Roberto, et al., "Revisiting the Ullmann-Ether Reaction: A Concise and Amenable Synthesis of Novel Dibenzoxepino[4,5-d]pyrazoles by INtramolecular Etheration of 4,5-(o,o'-Halohydroxy) arylpyrazoles" Journal of Organic Chemistry, 2002, Vol 67, pages 7215-7225.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	/Amy Lewis/	Date	11/08/2009
Signature	iring Lowisi	Considered	11/00/2009

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.



Application No. (if known): 10/595,934

Attorney Docket No.: 03818/0204417-US0

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to: \$\mathbb{M} 8 3 4 7 3 1 5 4 0 \mu\mathbb{S}\$

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on October 20, 2006

Date

d. Sta	atlai
Signatu	antini
Typed or printed name of per	rson signing Certificate
Registration Number, if applicable	Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2pages) (30 References) Information Disclosure Statement (5 pages) Return Receipt Postcard